"Three-Person IVF" Update Reveals How Little We Know
By Jessica Cussins,
The Huffington Post
| 06. 05. 2014
Three-person IVF is a critical departure from the traditional kind. This new and biologically extreme technique, which has generated scientific and bioethical controversy on both sides of the Atlantic, would combine genetic material from one man and two women in a single embryo. It is currently prohibited in the United Kingdom, but has been heavily promoted by its developers, and the law could be changed as soon as this year to allow it to move into fertility clinics.
The technique under consideration is being proposed for women with a rare form of mitochondrial disease who wish to have an unaffected and mostly genetically related child. It requires the extraction of the nucleus from her egg or embryo followed by its reinsertion into another woman's egg or embryo. Any resulting child would inherit nuclear DNA from the intended mother and mitochondrial DNA from an anonymous egg provider.
The UK's fertility regulator, the Human Fertilisation and Embryology Authority (HFEA) has just released an update on the safety and efficacy of this "three-person IVF." The HFEA report will help inform the upcoming Parliamentary...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...